<DOC>
	<DOCNO>NCT02887482</DOCNO>
	<brief_summary>The clinical trial ass safety , tolerability , immunogenicity GLS-5700 . GLS-5700 synthetic DNA plasmid vaccine Zika virus . This Phase 1 clinical trial vaccine encode premembrane-membrane envelope region Zika virus . Zika virus , first discover Zika forest 1947 , cause large epidemic South America , Central America , Caribbean islands commence late 2014 early 2015 . Zika virus cause significant neurologic disease include Guillain Barre Syndrome adult microcephaly birth defect among child bear mother infected pregnancy . At present vaccine treatment approve Zika virus infection .</brief_summary>
	<brief_title>Study GLS-5700 Dengue Virus Seropositive Adults</brief_title>
	<detailed_description>GLS-5700 contains single plasmid contain DNA encode pre-membrane envelope ( prME ) proteins Zika virus .</detailed_description>
	<criteria>Age 1865 year ; Able provide consent participate sign Informed Consent Form ( ICF ) ; Able willing comply study procedure ; Women childbearing potential agree use medically effective contraception ( oral contraception , barrier method , spermicide , etc . ) partner sterile enrollment 3 month follow last injection , partner medically unable induce pregnancy . Sexually active men consider sexually fertile must agree use either barrier method contraception study , agree continue use least 3 month follow last injection , partner permanently sterile medically unable become pregnant ; Seropositive dengue virus infection . Normal screen ECG screen ECG clinically significant finding ; Screening lab must within normal limit Grade 01 finding , except creatinine may grade 2 baseline ; No history clinically significant immunosuppressive autoimmune disease . No history dengue virus vaccination ; history yellow fever vaccination Not currently within previous 4 week take immunosuppressive agent ( exclude inhale , topical skin and/or eye dropcontaining corticosteroid , lowdose methotrexate , prednisone dose le 10 mg/day , steroid equivalent ) . Administration investigational compound either currently within 30 day first dose ; Previous receipt investigational product treatment prevention Zika virus infection except subject verify received placebo ; Administration vaccine within 4 week first dose ; Administration monoclonal polyclonal antibody product within 4 week first dose Administration blood product within 3 month first dose ; Pregnancy breast feed plan become pregnant course study ; Negative serologic result dengue virus ( serotype ) history receipt either dengue virus yellow fever virus vaccination time past ; Positive serologic test HIV , hepatitis B surface antigen ( HBsAg ) ; potentially communicable infectious disease determine Principal Investigator Medical Monitor ; Positive serologic test hepatitis C ( exception : successful treatment confirmation sustain virologic response ) ; Baseline evidence kidney disease measure creatinine great 1.5 ( CKD Stage II great ) ; Baseline screen lab ( ) Grade 2 high abnormality ; Chronic liver disease cirrhosis ; Immunosuppressive illness include hematologic malignancy , history solid organ bone marrow transplantation ; Current anticipate concomitant immunosuppressive therapy ( exclude inhale , topical skin and/or eye dropcontaining corticosteroid , lowdose methotrexate , prednisone dose equal great 10 mg/day , steroid equivalent ) ; Current anticipate treatment TNFÎ± inhibitor infliximab , adalimumab , etanercept ; Prior major surgery radiation therapy within 4 week group assignment ; Any preexcitation syndrome , e.g. , WolffParkinsonWhite syndrome ; Presence cardiac pacemaker automatic implantable cardioverter defibrillator ( AICD ) Metal implant within 20 cm plan site ( ) injection ; Presence keloid scar formation hypertrophic scar clinically significant medical condition plan site ( ) injection . Prisoner subject compulsorily detain ( involuntary incarceration ) treatment either physical psychiatric illness ; Active drug alcohol use dependence , opinion investigator , would interfere adherence study requirement assessment immunologic endpoint ; Not willing allow storage future use sample Zika virus relate research Any illness condition opinion investigator may affect safety subject evaluation study endpoint .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>DNA</keyword>
	<keyword>Vaccine</keyword>
</DOC>